Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 2Phase NA 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Other 1

Conditions

Prostatic Neoplasms 2Sexual Dysfunction, Physiological 1Erectile Dysfunction 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Tadalafil × Clear all
NCT00931528 2018-02-14

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group

Phase 3 Completed
242 enrolled 13 charts
GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

NCT00122499 2005-07-27

A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer

Erasmus Medical Center

Phase 3 Completed
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡